Divi's Laboratories Limited — Investor Meet, 14-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Divi's Labs reported Q3FY26 consolidated income of ₹2,692 Cr (up from ₹2,401 Cr YoY) and PAT of ₹583 Cr, after a ₹74 Cr exceptional employee benefit item. For the nine months, constant currency growth was 8.6%, with income at ₹8,081 Cr and PAT at ₹1,817 Cr.

Management noted stable generic volumes despite pricing pressures and multiple Custom Synthesis projects nearing commercialization in the next year. Three dedicated CS projects are anticipated to go live in Q3/Q4 calendar year 2027. Unit 3 (Kakinada) is crucial for backward integration, freeing up other unit capacities. A successful US FDA inspection at Unit 1 reaffirmed quality. The company is diversifying raw material sourcing, with domestic suppliers now at 78%. Capacity utilization stands at 70-80%. Management conveys confidence in its growth trajectory, balancing new products with off-patent ones.